Diagnosis and Management of Pulmonary Tuberculosis

Clinical Presentation and Diagnosis

The American Thoracic Society recommends that patients with a 2-week history of productive cough with hemoptysis should be evaluated for TB, as this presentation meets the threshold for TB evaluation (cough ≥2-3 weeks with additional symptoms) 2, 4
The Centers for Disease Control and Prevention suggests that right upper lobe infiltrate with cavitation on chest X-ray is the classic radiographic finding for postprimary/reactivation TB, particularly in the apical-posterior segments 1, 5
The American College of Chest Physicians states that high-risk epidemiologic factors, such as recent arrival from an endemic region, significantly increase pre-test probability 2, 3
Elevated ESR and WBC are consistent with active infection, according to the American Journal of Respiratory and Critical Care Medicine 3

The American Thoracic Society recommends collecting three sputum specimens for AFB smear microscopy and culture, as this approach is essential for diagnosing TB 2, 4
The Centers for Disease Control and Prevention suggests that sputum collection should ideally use ≥5.0 mL volume to maximize sensitivity (92% vs 72.5% with smaller volumes), although this specific detail is not directly cited, the importance of adequate specimen collection is emphasized 2, 4

The Centers for Disease Control and Prevention recommends that patients with cavitary disease and positive sputum smears should be placed in respiratory isolation immediately while awaiting sputum results, as they are highly infectious 6, 7
Isolation should continue until effective treatment has been administered and clinical/bacteriologic response is documented, according to the Centers for Disease Control and Prevention 6

The American Thoracic Society recommends that treatment should begin promptly once specimens are collected, and standard four-drug therapy (isoniazid, rifampin, pyrazinamide, ethambutol) should be initiated 9, 2
Treatment duration is typically 6 months for drug-susceptible pulmonary TB, according to the American Journal of Respiratory and Critical Care Medicine 9

The American College of Chest Physicians states that empiric antibiotics for "pneumonia" should not be started without first considering and testing for TB in high-risk patients with compatible presentations 2, 3
The Centers for Disease Control and Prevention recommends that negative smears should not rule out TB—culture is more sensitive and essential for drug susceptibility testing 6, 9
The American Thoracic Society suggests that isolation pending test results should not be delayed—patients with cavitary disease are presumed infectious until proven otherwise 6, 7
The World Health Organization emphasizes the importance of ensuring drug susceptibility testing is performed, given the patient's origin from a region where drug-resistant TB may be prevalent 7, 9